To explore the potential molecular mechanisms involved in migratory glioma cells.
Methods
The gene expression profiles of GSE28167, employing human malignant glioma U251MG cells cultured on strictly aligned versus randomly oriented electrospun nanofibers of polycaprolactone, were downloaded from the Gene Expression Omnibus database. Gene differential expression analysis was carried out by the package of Gene Expression Omnibus query and limma in R language. The Gene Set Analysis Toolkit V2 was used for pathway analysis. Gene set enrichment analysis was used to screen for target sites of transcription factors, miRNA and small drug molecules.
Results
Totally 586 differentially expressed genes were identified and the differentially expressed genes were mainly enriched in the pathway of muscle cell TarBase, MAPK cascade, adipogenesis and epithelium TarBase. Thirty-two significant target sites of transcription factors, such as hsa_RTAAACA_V$FREAC2_01, were screened. The top 20 potential miRNAs including MIR-124A, MIR-34A and MIR-34C were screened for a constructing gene-miRNA interaction network. Small molecules that can inhibit the motility of glioma cells such as diclofenamide and valinomycin were mined. By integrating the regulatory relationships among transcription factors, miRNAs and differentially expressed genes, we found that 7 differentially expressed genes, including SOX4, ANKRD28 and CCND1, might play crucial roles in the migration of glioma cells.
Conclusions
The screened migration-associated genes, significant pathways, and small molecules give us new insight for the mechanism of migratory glioma cells. Interest in such genes as potential target genes in the treatment of glioblastoma justifies functional validation studies.
RamplingR., JamesA., PapanastassiouV.The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry.2004; 75: ii24–ii30.
2.
BucknerJ.C., BrownP.D., O'NeillB.P., MeyerF.B., WetmoreC.J., UhmJ.H.Central nervous system tumors. Mayo Clinic Proceed.2007. Elsevier.
3.
BeliënA.T., PaganettiP.A., SchwabM.E.Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol.1999; 144: 373–384.
4.
DavisF.G., McCarthyB.J.Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther.2001; 1: 395–401.
5.
ChintalaS.K., RaoJ.Invasion of human glioma: role of extracellular matrix proteins. Front Biosci.1996; 1: 324–339.
6.
MaherE.A., FurnariF.B., BachooR.M.Malignant glioma: genetics and biology of a grave matter. Genes Dev.2001; 15: 1311–1333.
7.
VeeravalliK.K., PonnalaS., ChettyC., TsungA.J., GujratiM., RaoJ.S.Integrin α9β1-mediated cell migration in glioblastoma via SSAT and Kir4. 2 potassium channel pathway. Cell Signal.2012; 24: 272–281.
8.
MouL., KangY., ZhouY., ZengQ., SongH., WangR.Neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1 matrix metalloproteinase (MT1-MMP). J Biol Chem.2013; 288(1): 306–318.
9.
ZhouX., XuX., MengQ.Bex2 is critical for migration and invasion in malignant glioma cells. J Mol Neurosci.2013; 1–10.
10.
QiS., SongY., PengY.ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE.2012; 7: e38842.
11.
BaiJ., MeiP-J, LiuH.BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. J Cancer Res Clin Oncol.2012; 138: 991–998.
MertschS., SchmitzN., JeibmannA., GengJ-G, PaulusW., SennerV: Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol.2008; 87: 1–7.
14.
GesslerF., VossV., SeifertV., GerlachR., KögelD.Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett.2011; 497: 49–54.
15.
MéndezO., ZavadilJ., EsencayM.Research knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres.2010; 9: 133.
16.
LeeH.K., BierA., CazacuS.MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS ONE.2013; 8: e54652.
17.
HuaD., DingD., HanX.Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Oncol Rep.2012; 27: 700–706.
18.
TuY., GaoX., LiG.MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res.2013; 73: 6046–6055.
19.
ChenL., ChenX-R, ZhangR.MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. J Neurooncol.2013; 112: 59–66.
20.
FowlerA., ThomsonD., GilesK.miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer.2011; 47: 953–963.
21.
GodlewskiJ., BroniszA., NowickiM.O., ChioccaE.A., LawlerS.mi-croRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle.2010; 9: 2814–2820.
JohnsonJ., NowickiM.O., LeeC.H.Quantitative analysis of complex glioma cell migration on electrospun polycaprolactone using time-lapse microscopy. Tissue Engineering Part C: Methods.2009; 15: 531–540.
24.
BarrettT., WilhiteS.E., LedouxP.NCBI GEO: archive for functional genomics data sets — update. Nucleic Acids Res.2013; 41: D991–D995.
25.
DavisS., MeltzerP.S.GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics.2007; 23: 1846–1847.
26.
DibounI., WernischL., OrengoC.A., KoltzenburgM.Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics.2006; 7: 252.
27.
KelderT., van IerselM.P., HanspersK.WikiPathways: building research communities on biological pathways. Nucleic Acids Res.2012; 40: D1301–D1307.
28.
BenjaminiY., HochbergY.Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Society. Series B (Methodological).1995; 57: 289–300.
29.
SubramanianA., TamayoP., MoothaV.K.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA.2005; 102: 15545–15550.
30.
ShannonP., MarkielA., OzierO.Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res.2003; 13: 2498–2504.
31.
LambJ., CrawfordE.D., PeckD.The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006; 313: 1929–1935.
32.
LeeH., KangR., HahnY.Antiobesity effect of baicalin involves the modulations of proadipogenic and antiadipo-genic regulators of the adipogenesis pathway. Phytother Res.2009; 23: 1615–1623.
33.
FogelM., GorelikE., SegalS., FeldmanM.Differences in cell surface antigens of tumor metastases and those of the local tumor. J Natl Cancer Inst.1979; 62: 585–588.
34.
SegerR., KrebsE.: The MAPK signaling cascade. FASEB J.1995; 9: 726–735.
35.
VerhaakR.G., HoadleyK.A., PurdomE.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRa, IDH1, EGFR, and NF1. Cancer Cell.2010; 17: 98–110.
36.
GianniniC., SarkariaJ.N., SaitoA.Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncology.2005; 7: 164–176.
37.
OzawaT., BrennanC.W., WangL.PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev.2010; 24: 2205–2218.
38.
LinB., MadanA., YoonJ-GMassively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS ONE.2010; 5: e10210.
39.
AktasH., CaiH., CooperG.M.Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol.1997; 17: 3850–3857.
40.
MauriceD.H., PalmerD., TilleyD.G.Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol.2003; 64: 533–546.
41.
WaiteA., TinsleyC.L., LockeM., BlakeD.J.The neurobiology of the dystrophin-associated glycoprotein complex. Ann Med.2009; 41: 344–359.
42.
MatsunagaE., NakamuraH., ChédotalA.Repulsive guidance molecule plays multiple roles in neuronal differentiation and axon guidance. J Neuroscience.2006; 26: 6082–6088.
43.
ReardonD.A., QuinnJ.A., VredenburghJ.J.Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res.2006; 12: 860–868.
44.
LeonardA., WolffJ.E.Etoposide improves survival in high-grade glioma: a meta-analysis. Anticancer Res.2013; 33: 3307–3315.
